cardioКардиологияKardiologiia0022-90402412-5660Kardiomag10.18087/cardio.2021.4.n1369cardio-1369Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИRESEARCH ARTICLESАдипокины крови у молодых людей с ранней ишемической болезнью сердца на фоне абдоминального ожиренияBlood Adipokins in Young People with Early Ischemic Heart Disease on the Background of Abdominal ObesityРагиноЮ. И.RaginoYu. I.

Руководитель НИИТПМ - филиал ИЦиГ СО РАН

Член-корреспондент РАН, доктор медицинских наук, профессор

 

Director of IIPM – a branch of the ICG SB RAS

Corresponding member of RAS, Doctor of Medical Sciences, Professor

 

ragino@mail.ruЩербаковаЛ. В.ShcherbakovaL. V.

Старший научный сотрудник лаборатории клинико-популяционных и профилактических исследований терапевтических и эндокринных заболеваний

Senior Researcher of Laboratory of Clinical-Populational and Prophylactic Studies on Internal and Endocrine Diseases

9584792@mail.ruОблауховаВ. И.OblaukhovaV. I.

Младший научный сотрудник лаборатории клинических биохимических и гормональных исследований терапевтических заболеваний

Junior Researcher of Laboratory of Clinical Biochemical and Hormonal Studies on Internal Diseases

nikamedicine@mail.ruПолонскаяЯ. В.PolonskayaYa. V.

Старший научный сотрудник лаборатории клинических биохимических и гормональных исследований терапевтических заболеваний

Доктор биологических наук

Senior Researcher of Laboratory of Clinical Biochemical and Hormonal Studies on Internal Diseases

Doctor of Biological Sciences

yana-polonskaya@yandex.ruСтахневаЕ. М.StakhnevaE. M.

Старший научный сотрудник лаборатории клинических биохимических и гормональных исследований терапевтических заболеваний

Кандидат биологических наук

Senior Researcher of Laboratory of Clinical Biochemical and Hormonal Studies on Internal Diseases

Candidate of Biological Sciences

stahneva@yandex.ruКузьминыхН. А.KuzminykhN. A.

Младший научный сотрудник лаборатории клинических биохимических и гормональных исследований терапевтических заболеваний

Кандидат медицинских наук

Junior Researcher of Laboratory of Clinical Biochemical and Hormonal Studies on Internal Diseases

Candidate of Medical Sciences

tina87@inbox.ruКаштановаЕ. В.KashtanovaE. V.

Заведующая лабораторией клинических биохимических и гормональных исследований терапевтических заболеваний, старший научный сотрудник

Доктор биологических наук

 

Head of Laboratory of Clinical Biochemical and Hormonal Studies on Internal Diseases, Senior Researcher

Doctor of Biological Sciences

 

elekastanova@yandex.ruНаучно-исследовательский институт терапии и профилактической медицины – филиал ФГБНУ «Федеральный исследовательский центр Институт цитологии и генетики» СО РАН, НовосибирскРоссияThe Institute of Internal and Preventive Medicine – a branch of a federal publicly funded scientific institution, the federal research center Institute of Cytology and Genetics, NovosibirskRussian Federation2021040520216143238Copyright © Kardiomag, 20212021KardiomagKardiomaghttps://cardio.elpub.ru/jour/about/submissions#copyrightNoticehttps://cardio.elpub.ru/jour/article/view/1369

Цель    Изучение спектра адипокинов крови у людей в возрасте 25–44 лет с ранней ишемической болезнью сердца (ИБС), в том числе на фоне абдоминального ожирения (АО).

Материал и методы  Проведено одномоментное популяционное обследование случайной выборки населения в возрасте 25–44 лет г. Новосибирска. Обследованы 1457 человек (653 мужчины, 804 женщины). В данное исследование были включены 123 человека, из которых были сформированы 4 подгруппы обследованных: 1‑я – лица с ИБС на фоне АО (n=24); 2‑я – лица с ИБС без АО (n=25); 3‑я – лица без ИБС с АО (n=44); 4‑я – лица без ИБС и без АО (n=30). Одновременный анализ концентраций адипокинов в сыворотке крови проводили методами мультиплексного анализа на проточном флуориметре Luminex MAGPIX и иммуноферментного анализа на анализаторе MULTISCAN.

Результаты   У лиц с ранней ИБС выявлены более низкие, чем у лиц без ИБС, концентрации в крови адипсина и висфатина. У лиц с ранней ИБС на фоне АО в крови выявлены более высокие концентрации адипсина, ингибитора активатора плазминогена 1‑го типа и лептина и более низкие концентрации моноцитарного хемоаттрактантного белка 1‑го типа (MCP-1) и висфатина, по сравнению с лицами с ранней ИБС без АО. По данным многофакторного логистического регрессионного анализа, более низкая концентрация в крови MCP-1 ассоциирована с шансом наличия ранней ИБС.

Заключение     У молодых людей в возрасте 25–44 лет более низкая концентрация в крови MCP-1 ассоциирована с шансом наличия ранней ИБС, в том числе на фоне АО.

 

Aim      To study blood adipokines spectrum in people aged 25–44 years with early ischemic heart disease (IHD), including that associated with abdominal obesity (AO).

Material and methods  A cross-sectional study was performed on a random sample of the population aged 25–44 years in Novosibirsk. 1457 subjects (653 men, 804 women) were evaluated. This study included 123 people divided into four study subgroups: subgroup 1, with IHD associated with AO (n=24); subgroup 2, with IHD and without AO (n=25); subgroup 3, without IHD and with AO (n=44); and subgroup 4, without either IHD or AO (n=30). Concentrations of serum adipokines were measured simultaneously by multiplex assay with a Luminex MAGPIX flow fluorometer and by immune enzyme assay with a MULTISCAN analyzer.

Results Subjects with early IHD had lower blood concentrations of adipsin and visfatin than subjects without IHD. Subjects with early IHD associated with AO had higher blood concentrations of adipsin, plasminogen activator inhibitor-1, and leptin and lower concentrations of monocyte chemoattractant protein-1 (MCP-1) and visfatin compared to subjects with early IHD and without AO. The multivariate logistic regression analysis showed that lower blood concentrations of MCP-1 were associated with a likelihood of early IHD.

Conclusion      In young people aged 25–44 years, lower blood concentrations of MCP-1 were associated with a likelihood of early IHD, including that associated with AO.

Ранняя ишемическая болезнь сердцаабдоминальное ожирениеадипокины кровимоноцитарный хемоаттрактантный белок 1‑го типамультиплексный анализEarly ischemic heart diseaseabdominal obesityblood adipokinesmonocyte chemoattractant protein-1multiplex analysisКонфликт интересов не заявлен.No conflict of interest is reported.ReferencesRoth GA, Huffman MD, Moran AE, Feigin V, Mensah GA, Naghavi M et al. Global and Regional Patterns in Cardiovascular Mortality From 1990 to 2013. Circulation. 2015;132(17):1667–78. DOI: 10.1161/CIRCULATIONAHA.114.008720Roth GA, Huffman MD, Moran AE, Feigin V, Mensah GA, Naghavi M et al. Global and Regional Patterns in Cardiovascular Mortality From 1990 to 2013. Circulation. 2015;132(17):1667–78. DOI: 10.1161/CIRCULATIONAHA.114.008720Андреенко Е.Ю., Явелов И.С., Лукьянов М.М., Вернохаева А.Н., Драпкина О.М., Бойцов С.А. Ишемическая болезнь сердца у лиц молодого возраста: распространенность и сердечно-сосудистые факторы риска. Кардиология. 2018;58(10):53-8. DOI: 10.18087/cardio.2018.10.10184Andreenko E.Yu., Yavelov I.S., Loukianov M.M., Vernohaeva A.N., Drapkina O.M., Boytsov S.A. Ischemic Heart Disease in Subjects of Young Age: Current State of the Problem: Prevalence and Cardio-Vascular Risk Factors. Kardiologiia. 2018;58(10):53–8. DOI: 10.18087/cardio.2018.10.10184Krzysztoszek J, Laudańska-Krzemińska I, Bronikowski M. Assessment of epidemiological obesity among adults in EU countries. Annals of Agricultural and Environmental Medicine. 2019;26(2):341–9. DOI: 10.26444/aaem/97226Krzysztoszek J, Laudańska-Krzemińska I, Bronikowski M. Assessment of epidemiological obesity among adults in EU countries. Annals of Agricultural and Environmental Medicine. 2019;26(2):341–9. DOI: 10.26444/aaem/97226Neeland IJ, Ross R, Després J-P, Matsuzawa Y, Yamashita S, Shai I et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. The Lancet Diabetes & Endocrinology. 2019;7(9):715–25. DOI: 10.1016/S2213-8587(19)30084-1Neeland IJ, Ross R, Després J-P, Matsuzawa Y, Yamashita S, Shai I et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. The Lancet Diabetes & Endocrinology. 2019;7(9):715–25. DOI: 10.1016/S2213-8587(19)30084-1Chait A, den Hartigh LJ. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Frontiers in Cardiovascular Medicine. 2020;7:22. DOI: 10.3389/fcvm.2020.00022Chait A, den Hartigh LJ. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Frontiers in Cardiovascular Medicine. 2020;7:22. DOI: 10.3389/fcvm.2020.00022Kwaifa IK, Bahari H, Yong YK, Noor SM. Endothelial Dysfunction in Obesity-Induced Inflammation: Molecular Mechanisms and Clinical Implications. Biomolecules. 2020;10(2):291. DOI: 10.3390/biom10020291Kwaifa IK, Bahari H, Yong YK, Noor SM. Endothelial Dysfunction in Obesity-Induced Inflammation: Molecular Mechanisms and Clinical Implications. Biomolecules. 2020;10(2):291. DOI: 10.3390/biom10020291Francisco V, Pino J, Gonzalez-Gay MA, Mera A, Lago F, Gómez R et al. Adipokines and inflammation: is it a question of weight? Obesity and inflammatory diseases. British Journal of Pharmacology. 2018;175(10):1569–79. DOI: 10.1111/bph.14181Francisco V, Pino J, Gonzalez-Gay MA, Mera A, Lago F, Gómez R et al. Adipokines and inflammation: is it a question of weight? Obesity and inflammatory diseases. British Journal of Pharmacology. 2018;175(10):1569–79. DOI: 10.1111/bph.14181Ragino YI, Stakhneva EM, Polonskaya YV, Kashtanova EV. The Role of Secretory Activity Molecules of Visceral Adipocytes in Abdominal Obesity in the Development of Cardiovascular Disease: A Review. Biomolecules. 2020;10(3):374. DOI: 10.3390/biom10030374Ragino YI, Stakhneva EM, Polonskaya YV, Kashtanova EV. The Role of Secretory Activity Molecules of Visceral Adipocytes in Abdominal Obesity in the Development of Cardiovascular Disease: A Review. Biomolecules. 2020;10(3):374. DOI: 10.3390/biom10030374Ha EE, Bauer RC. Emerging Roles for Adipose Tissue in Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2018;38(8):e137–44. DOI: 10.1161/ATVBAHA.118.311421Ha EE, Bauer RC. Emerging Roles for Adipose Tissue in Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 2018;38(8):e137–44. DOI: 10.1161/ATVBAHA.118.311421Carbone S, Canada JM, Billingsley HE, Siddiqui MS, Elagizi A, Lavie CJ. Obesity paradox in cardiovascular disease: where do we stand? Vascular Health and Risk Management. 2019;15:89–100. DOI: 10.2147/VHRM.S168946Carbone S, Canada JM, Billingsley HE, Siddiqui MS, Elagizi A, Lavie CJ. Obesity paradox in cardiovascular disease: where do we stand? Vascular Health and Risk Management. 2019;15:89–100. DOI: 10.2147/VHRM.S168946Dutheil F, Gordon BA, Naughton G, Crendal E, Courteix D, Chaplais E et al. Cardiovascular risk of adipokines: a review. Journal of International Medical Research. 2018;46(6):2082–95. DOI: 10.1177/0300060517706578Dutheil F, Gordon BA, Naughton G, Crendal E, Courteix D, Chaplais E et al. Cardiovascular risk of adipokines: a review. Journal of International Medical Research. 2018;46(6):2082–95. DOI: 10.1177/0300060517706578Otelea MR, Streinu-Cercel A, Băicus C, Maria Nitescu M. The Adipokine Profile and the Cardiometabolic Risk in Non-Obese Young Adults. Balkan Medical Journal. 2019;36(3):155–61. DOI: 10.4274/balkanmedj.galenos.2018.2018.0789Otelea MR, Streinu-Cercel A, Băicus C, Maria Nitescu M. The Adipokine Profile and the Cardiometabolic Risk in Non-Obese Young Adults. Balkan Medical Journal. 2019;36(3):155–61. DOI: 10.4274/balkanmedj.galenos.2018.2018.0789Pello AM, Cristóbal C, Tarín N, Huelmos A, Aceña Á, Carda R et al. Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors. Journal of Cardiology. 2015;66(1):22–7. DOI: 10.1016/j.jjcc.2014.11.006Pello AM, Cristóbal C, Tarín N, Huelmos A, Aceña Á, Carda R et al. Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors. Journal of Cardiology. 2015;66(1):22–7. DOI: 10.1016/j.jjcc.2014.11.006Yu F, Li J, Huang Q, Cai H. Increased Peripheral Blood Visfatin Concentrations May Be a Risk Marker of Coronary Artery Disease: A Meta-Analysis of Observational Studies. Angiology. 2018;69(9):825–34. DOI: 10.1177/0003319718771125Yu F, Li J, Huang Q, Cai H. Increased Peripheral Blood Visfatin Concentrations May Be a Risk Marker of Coronary Artery Disease: A Meta-Analysis of Observational Studies. Angiology. 2018;69(9):825–34. DOI: 10.1177/0003319718771125Ohtsuki T, Satoh K, Shimizu T, Ikeda S, Kikuchi N, Satoh T et al. Identification of Adipsin as a Novel Prognostic Biomarker in Patients With Coronary Artery Disease. Journal of the American Heart Association. 2019;8(23):e013716. DOI: 10.1161/JAHA.119.013716Ohtsuki T, Satoh K, Shimizu T, Ikeda S, Kikuchi N, Satoh T et al. Identification of Adipsin as a Novel Prognostic Biomarker in Patients With Coronary Artery Disease. Journal of the American Heart Association. 2019;8(23):e013716. DOI: 10.1161/JAHA.119.013716Tafere GG, Wondafrash DZ, Zewdie KA, Assefa BT, Ayza MA. Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020;13:1855–61. DOI: 10.2147/DMSO.S253967Tafere GG, Wondafrash DZ, Zewdie KA, Assefa BT, Ayza MA. Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020;13:1855–61. DOI: 10.2147/DMSO.S253967Lo JC, Ljubicic S, Leibiger B, Kern M, Leibiger IB, Moede T et al. Adipsin Is an Adipokine that Improves β Cell Function in Diabetes. Cell. 2014;158(1):41–53. DOI: 10.1016/j.cell.2014.06.005Lo JC, Ljubicic S, Leibiger B, Kern M, Leibiger IB, Moede T et al. Adipsin Is an Adipokine that Improves β Cell Function in Diabetes. Cell. 2014;158(1):41–53. DOI: 10.1016/j.cell.2014.06.005Yarmolinsky J, Bordin Barbieri N, Weinmann T, Ziegelmann PK, Duncan BB, Schmidt MI. Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies. Scientific Reports. 2016;6(1):17714. DOI: 10.1038/srep17714Yarmolinsky J, Bordin Barbieri N, Weinmann T, Ziegelmann PK, Duncan BB, Schmidt MI. Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies. Scientific Reports. 2016;6(1):17714. DOI: 10.1038/srep17714Smits MM, Woudstra P, Utzschneider KM, Tong J, Gerchman F, Faulenbach M et al. Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis. Annals of Epidemiology. 2013;23(7):415–21. DOI: 10.1016/j.annepidem.2013.03.001Smits MM, Woudstra P, Utzschneider KM, Tong J, Gerchman F, Faulenbach M et al. Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis. Annals of Epidemiology. 2013;23(7):415–21. DOI: 10.1016/j.annepidem.2013.03.001Tofler GH, Massaro J, O’Donnell CJ, Wilson PWF, Vasan RS, Sutherland PA et al. Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study. Thrombosis Research. 2016;140:30–5. DOI: 10.1016/j.thromres.2016.02.002Tofler GH, Massaro J, O’Donnell CJ, Wilson PWF, Vasan RS, Sutherland PA et al. Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study. Thrombosis Research. 2016;140:30–5. DOI: 10.1016/j.thromres.2016.02.002Meltzer ME, Doggen CJM, de Groot PG, Rosendaal FR, Lisman T. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. Blood. 2010;116(4):529–36. DOI: 10.1182/blood-2010-01-263103Meltzer ME, Doggen CJM, de Groot PG, Rosendaal FR, Lisman T. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. Blood. 2010;116(4):529–36. DOI: 10.1182/blood-2010-01-263103Singh M, Bedi US, Singh PP, Arora R, Khosla S. Leptin and the clinical cardiovascular risk. International Journal of Cardiology. 2010;140(3):266–71. DOI: 10.1016/j.ijcard.2009.07.019Singh M, Bedi US, Singh PP, Arora R, Khosla S. Leptin and the clinical cardiovascular risk. International Journal of Cardiology. 2010;140(3):266–71. DOI: 10.1016/j.ijcard.2009.07.019Sierra-Johnson J, Romero-Corral A, Lopez-Jimenez F, Gami AS, Sert Kuniyoshi FH, Wolk R et al. Relation of Increased Leptin Concentrations to History of Myocardial Infarction and Stroke in the United States Population. The American Journal of Cardiology. 2007;100(2):234–9. DOI: 10.1016/j.amjcard.2007.02.088Sierra-Johnson J, Romero-Corral A, Lopez-Jimenez F, Gami AS, Sert Kuniyoshi FH, Wolk R et al. Relation of Increased Leptin Concentrations to History of Myocardial Infarction and Stroke in the United States Population. The American Journal of Cardiology. 2007;100(2):234–9. DOI: 10.1016/j.amjcard.2007.02.088Kappelle PJWH, Dullaart RPF, van Beek AP, Hillege HL, Wolffenbuttel BHR. The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: A prospective nested case–control study. European Journal of Internal Medicine. 2012;23(8):755–9. DOI: 10.1016/j.ejim.2012.06.013Kappelle PJWH, Dullaart RPF, van Beek AP, Hillege HL, Wolffenbuttel BHR. The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: A prospective nested case–control study. European Journal of Internal Medicine. 2012;23(8):755–9. DOI: 10.1016/j.ejim.2012.06.013Auguet T, Aragonès G, Guiu-Jurado E, Berlanga A, Curriu M, Martinez S et al. Adipo/cytokines in atherosclerotic secretomes: increased visfatin levels in unstable carotid plaque. BMC cardiovascular disorders. 2016;16(1):149. DOI: 10.1186/s12872-016-0320-5Auguet T, Aragonès G, Guiu-Jurado E, Berlanga A, Curriu M, Martinez S et al. Adipo/cytokines in atherosclerotic secretomes: increased visfatin levels in unstable carotid plaque. BMC cardiovascular disorders. 2016;16(1):149. DOI: 10.1186/s12872-016-0320-5Zheng L-Y, Xu X, Wan R-H, Xia S, Lu J, Huang Q. Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes. Diabetology & Metabolic Syndrome. 2019;11(1):60. DOI: 10.1186/s13098-019-0455-5Zheng L-Y, Xu X, Wan R-H, Xia S, Lu J, Huang Q. Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes. Diabetology & Metabolic Syndrome. 2019;11(1):60. DOI: 10.1186/s13098-019-0455-5Bremer AA, Devaraj S, Afify A, Jialal I. Adipose Tissue Dysregulation in Patients with Metabolic Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2011;96(11):E1782–8. DOI: 10.1210/jc.2011-1577Bremer AA, Devaraj S, Afify A, Jialal I. Adipose Tissue Dysregulation in Patients with Metabolic Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2011;96(11):E1782–8. DOI: 10.1210/jc.2011-1577Arner E, Mejhert N, Kulyte A, Balwierz PJ, Pachkov M, Cormont M et al. Adipose Tissue MicroRNAs as Regulators of CCL2 Production in Human Obesity. Diabetes. 2012;61(8):1986–93. DOI: 10.2337/db11-1508Arner E, Mejhert N, Kulyte A, Balwierz PJ, Pachkov M, Cormont M et al. Adipose Tissue MicroRNAs as Regulators of CCL2 Production in Human Obesity. Diabetes. 2012;61(8):1986–93. DOI: 10.2337/db11-1508Amano SU, Cohen JL, Vangala P, Tencerova M, Nicoloro SM, Yawe JC et al. Local Proliferation of Macrophages Contributes to Obesity-Associated Adipose Tissue Inflammation. Cell Metabolism. 2014;19(1):162–71. DOI: 10.1016/j.cmet.2013.11.017Amano SU, Cohen JL, Vangala P, Tencerova M, Nicoloro SM, Yawe JC et al. Local Proliferation of Macrophages Contributes to Obesity-Associated Adipose Tissue Inflammation. Cell Metabolism. 2014;19(1):162–71. DOI: 10.1016/j.cmet.2013.11.017Inouye KE, Shi H, Howard JK, Daly CH, Lord GM, Rollins BJ et al. Absence of CC Chemokine Ligand 2 Does Not Limit Obesity-Associated Infiltration of Macrophages Into Adipose Tissue. Diabetes. 2007;56(9):2242–50. DOI: 10.2337/db07-0425Inouye KE, Shi H, Howard JK, Daly CH, Lord GM, Rollins BJ et al. Absence of CC Chemokine Ligand 2 Does Not Limit Obesity-Associated Infiltration of Macrophages Into Adipose Tissue. Diabetes. 2007;56(9):2242–50. DOI: 10.2337/db07-0425Cranford TL, Enos RT, Velázquez KT, McClellan JL, Davis JM, Singh UP et al. Role of MCP-1 on inflammatory processes and metabolic dysfunction following high-fat feedings in the FVB/N strain. International Journal of Obesity. 2016;40(5):844–51. DOI: 10.1038/ijo.2015.244Cranford TL, Enos RT, Velázquez KT, McClellan JL, Davis JM, Singh UP et al. Role of MCP-1 on inflammatory processes and metabolic dysfunction following high-fat feedings in the FVB/N strain. International Journal of Obesity. 2016;40(5):844–51. DOI: 10.1038/ijo.2015.244

The authors declare that there are no conflicts of interest present.